Table 1.
Baseline characteristics of patients with hepatitis C virus (HCV) genotype 1 treated with elbasvir/grazoprevir
| Characteristic | n = 353 |
|---|---|
| Age, years | 72 (38–90) |
| >75 | 144 (40.8) |
| Male : female, n | 159:194 |
| History of IFN therapy, no/yes (yes %) | 284/67 (19.1) |
| History of DAA therapy, no/yes (yes %) | 326/16 (4.7) |
| History of HCC, no/yes (yes %) | 316/37 (10.5) |
| Cirrhosis, no/yes (yes %) | 263/68 (20.5) |
| NS5A‐L31, wild‐type/mutant (mutant %) | 279/18 (6.1) |
| NS5A‐Y93, wild‐type/mutant (mutant %) | 249/48 (16.2) |
| Platelet count, ×103/μL | 125 (34–684) |
| AST, IU/L | 53 (8–484) |
| ALT, IU/L | 36 (7–470) |
| eGFR, mL/min/1.73 m2 | 62.5 (3.6–112.9) |
| G3a or G3b | 92 (26.1) |
| G4 or G5 | 56 (15.9) |
| M2BPGi, COI | 1.93 (0.25–14.2) |
| FIB‐4 index | 2.97 (0.36–17.2) |
| α‐Fetoprotein, ng/mL | 4 (1–296) |
| HCVRNA, log IU/mL | 6.1 (2.0–7.4) |
Data are shown as n (%) or median (range), unless otherwise indicated.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; COI, cut‐off index; DAA, direct‐acting antiviral; eGFR, estimated glomerular filtration rate; FIB‐4, Fibrosis‐4; HCC, hepatocellular carcinoma; IFN, interferon; M2BPGi, Mac‐2 binding protein glycosylation isomer; NS5A, non‐structural protein 5A.